Immunogenicity, safety, and effectiveness of seasonal influenza vaccination in patients with diabetes mellitus: A systematic review
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Influenza is associated with an increased risk of complications, especially in diabetic mellitus patients who are more susceptible to influenza infection. Despite recommendations of the WHO and public health authorities, vaccination uptake in this population remains suboptimal. This systematic review identified 15 studies published between January 2000-March 2017 in PubMed, Embase and Cochrane Library, which provided data on immunogenicity, safety, effectiveness, and/or cost-effectiveness of seasonal influenza vaccination in diabetic patients. Immunogenicity of seasonal influenza vaccination in diabetic patients was generally comparable to that of healthy participants. One month after vaccination of diabetic patients, seroconversion rates and seroprotection ranged from 24.0-58.0% and 29.0-99.0%, respectively. Seasonal influenza vaccination reduced the risk of hospitalization and mortality in diabetic patients, particularly those aged ≥65 years. These review results demonstrate and reinforce the need and value of annual influenza vaccination in diabetic patients, particularly in alleviating severe complications such as hospitalization or death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Overall, there is no evidence that incretin-based therapies increase risk for medullary thyroid carcinoma in humans.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1808]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Retrospective and meta-analysis of data from large placebo-controlled clinical trials with GLP-1 RAs and DPP-4 inhibitors have not found an increased risk of pancreatic cancer.1034,1807,1808”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1808]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“meta-analyses have not uncovered increased risk for thyroid cancer with GLP-1 RAs or DPP-4 inhibitors.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1808]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Vaccines for preventing influenza in healthy adults
Jefferson, T., Di Pietrantonj, C., Rivetti, A., Bawazeer, G. A., Al-Ansary, L. A., & Ferroni, E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001269.pub4 · Cited by 896
Diabetes mellitus statistics on prevalence and mortality: facts and fallacies
Zimmet, P., Alberti, K. G., Magliano, D. J., & Bennett, P. H. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.105 · Cited by 785
Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis
Mertz, D., Kim, T. H., Johnstone, J., Lam, P.-P., Science, M., Kuster, S. P., Fadel, S. A., Tran, D., Fernandez, E., Bhatnagar, N., et al. (2013) · BMJ · doi:10.1136/bmj.f5061 · Cited by 634
Grohskopf, L. A., Sokolow, L. Z., Broder, K. R., Olsen, S. J., Karron, R. A., Jernigan, D. B., & Bresee, J. S. (2016) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6505a1 · Cited by 593
Evidence of bias in estimates of influenza vaccine effectiveness in seniors
Jackson, L. A., Jackson, M. L., Nelson, J. C., Neuzil, K. M., & Weiss, N. S. (2006) · International Journal of Epidemiology · doi:10.1093/ije/dyi274 · Cited by 493
Vaccine Epidemiology: Efficacy, Effectiveness, and the Translational Research Roadmap
Weinberg, G. A., & Szilagyi, P. G. (2010) · The Journal of Infectious Diseases · doi:10.1086/652404 · Cited by 229
Hak, E., Nordin, J., Wei, F., Mullooly, J., Poblete, S., Strikas, R., & Nichol, K. L. (2002) · Clinical Infectious Diseases · doi:10.1086/341403 · Cited by 218
Research works printed but not linked: 2
- World Health Organization, 2003, Prevention and control of influenza pandemics and annual epidemics
- Villarroel MA, 2016, NCHS Data Brief., 1
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Samson, S. L., Vellanki, P., Blonde, L., Christofides, E. A., Galindo, R. J., Hirsch, I. B., Isaacs, S. D., Izuora, K. E., Low Wang, C. C., Twining, C. L., et al. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.02.001 · Cited by 375
Type 2 Diabetes: How Much of an Autoimmune Disease?
de Candia, P., Prattichizzo, F., Garavelli, S., Rosa, V. D., Galgani, M., Rella, F. D., Spagnuolo, M. I., Colamatteo, A., Fusco, C., Micillo, T., et al. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00451 · Cited by 130
Who and when to vaccinate against influenza
Buchy, P., & Badur, S. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.02.040 · Cited by 122
Lampasona, V., Secchi, M., Scavini, M., Bazzigaluppi, E., Brigatti, C., Marzinotto, I., Davalli, A. M., Caretto, A., Laurenzi, A., Martinenghi, S., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05284-4 · Cited by 119
Metadata
- Authors
- Dos Santos, G., Tahrat, H., & Bekkat-Berkani, R.
- Affiliations
- GSK, Wavre, Belgium
- GSK, Rockville, MD, USA
- GlaxoSmithKline (United States) (US)
- Venue
- Human Vaccines & Immunotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2018-04-09
- Volume
- 14
- Issue
- 8
- Pages
- 1853-1866
- ISSN
- 2164-5515 (ISSN-L)
- 2164-554X
- PMC
- PMC6149986
- OpenAlex
- W2793270909
- Cited by
- 83
- References
- 34
- Citations by year
- 2026: 2 · 2025: 12 · 2024: 11 · 2023: 11 · 2022: 17 · 2021: 11 · 2020: 10 · 2019: 6 · 2018: 3
- FWCI
- 1.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Human Vaccines & Immunotherapeutics (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Keywords
- seasonal influenza vaccination, diabetes mellitus, immunogenicity, vaccine safety, vaccine effectiveness, seroconversion, seroprotection, hospitalization, mortality, cost-effectiveness, vaccine uptake
- MeSH terms
- Immunogenicity, Vaccine, Cost-Benefit Analysis, Diabetes Mellitus, Humans, Influenza, Human, Influenza Vaccines, Influenza A virus, Quality of Life, Seasons, Vaccination, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunogenicity, safety, and effectiveness of seasonal influenza vaccination in patients with diabetes mellitus: A systematic review. https://app.cochat.ai/papers/10.1080/21645515.2018.1446719
- The paper
- Dos Santos, G., Tahrat, H., & Bekkat-Berkani, R. (2018). Immunogenicity, safety, and effectiveness of seasonal influenza vaccination in patients with diabetes mellitus: A systematic review. Human Vaccines & Immunotherapeutics. https://doi.org/10.1080/21645515.2018.1446719
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
